This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Lung cancer	ADAM9; CUB domain containing protein 1 (CDCP1)	<p>Studies in patient samples and mice suggest inhibiting ADAM9 or CDCP1 could help prevent metastasis in patients with lung cancer. In mice, injection of lung cancer cells with shRNA knockdown of <i>ADAM9</i> or <i>CDCP1</i> led to less metastasis to brain, bone and lung than injection of cells with control shRNA. In samples from patients with lung cancer, high ADAM9 expression was associated with brain metastases and high ADAM9 and CDCP1 levels correlated with poor prognosis. Ongoing studies include identifying compounds that block the ADAM9-CDCP1 signaling axis for lung cancer treatment. Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. Ltd. market Sprycel dasatinib to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).</p> <p>SciBX 7(33); doi:10.1038/scibx.2014.981 Published online Aug. 28, 2014</p>	Unpatented; licensing status not applicable	<p>Lin, C.-Y. <i>et al. Cancer Res.</i>; published online July 24, 2014; doi:10.1158/0008-5472.CAN-13-2995 Contact: Yuh-Pyng Sher, China Medical University Hospital, Taichung, Taiwan e-mail: ypsher@gmail.com</p>